Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
Mark J. Levis(Sidney Kimmel Cancer Center), Erkut Bahceci(Astellas Pharma (United States)), Charles Y. Liu(University of Southern California), Briana Sargent(Astellas Pharma (United States)), Jessica K. Altman(Northwestern University), Stephen A. Strickland(Vanderbilt University), Gary J. Schiller(Fred Hutch Cancer Center), Alexander E. Perl(University of Pennsylvania), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Maria R. Baer(University of Maryland, Baltimore), Celalettin Üstün(Rush University Medical Center), Richard A. Larson(Urbana University), Ellen K. Ritchie(Cornell University), Mark R. Litzow(Mayo Clinic in Arizona), Stan Gill(Astellas Pharma (United States)), David F. Claxton(The University of Texas MD Anderson Cancer Center), Catherine C. Smith(University of California, San Francisco), Jörge E. Cortes(Augusta University Health)
Cited by 39
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k